Wellbiotec Co., Ltd. (KRX:010600)

Wellbiotec Statistics

Total Valuation

Wellbiotec has a market cap or net worth of KRW 2.18 billion. The enterprise value is -2.86 billion.

Market Cap	2.18B
Enterprise Value	-2.86B

Important Dates

The next estimated earnings date is Wednesday, April 1, 2026.

Earnings Date	Apr 1, 2026
Ex-Dividend Date	n/a

Share Statistics

Wellbiotec has 90.92 million shares outstanding. The number of shares has decreased by -13.41% in one year.

Current Share Class	90.92M
Shares Outstanding	90.92M
Shares Change (YoY)	-13.41%
Shares Change (QoQ)	n/a
Owned by Insiders (%)	n/a
Owned by Institutions (%)	0.54%
Float	84.55M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	0.03
PB Ratio	0.14
P/TBV Ratio	0.15
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	0.19
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	1.15

Financial Position

The company has a current ratio of 2.06, with a Debt / Equity ratio of 0.08.

Current Ratio	2.06
Quick Ratio	1.59
Debt / Equity	0.08
Debt / EBITDA	n/a
Debt / FCF	-0.51
Interest Coverage	-5.69

Financial Efficiency

Return on equity (ROE) is -60.45% and return on invested capital (ROIC) is -11.84%.

Return on Equity (ROE)	-60.45%
Return on Assets (ROA)	-8.61%
Return on Invested Capital (ROIC)	-11.84%
Return on Capital Employed (ROCE)	-27.64%
Revenue Per Employee	11.40B
Profits Per Employee	-2.18B
Employee Count	7
Asset Turnover	2.47
Inventory Turnover	n/a

Taxes

In the past 12 months, Wellbiotec has paid 280.23 million in taxes.

Income Tax	280.23M
Effective Tax Rate	n/a

Stock Price Statistics

Beta (5Y)	1.30
52-Week Price Change	n/a
50-Day Moving Average	n/a
200-Day Moving Average	n/a
Relative Strength Index (RSI)	n/a
Average Volume (20 Days)	n/a

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Wellbiotec had revenue of KRW 79.77 billion and -15.25 billion in losses. Loss per share was -193.20.

Revenue	79.77B
Gross Profit	9.41B
Operating Income	-4.46B
Pretax Income	-12.97B
Net Income	-15.25B
EBITDA	-3.17B
EBIT	-4.46B
Loss Per Share	-193.20

Balance Sheet

The company has 6.32 billion in cash and 1.28 billion in debt, with a net cash position of 5.05 billion or 55.49 per share.

Cash & Cash Equivalents	6.32B
Total Debt	1.28B
Net Cash	5.05B
Net Cash Per Share	55.49
Equity (Book Value)	15.50B
Book Value Per Share	170.52
Working Capital	9.54B

Cash Flow

In the last 12 months, operating cash flow was -2.44 billion and capital expenditures -45.33 million, giving a free cash flow of -2.49 billion.

Operating Cash Flow	-2.44B
Capital Expenditures	-45.33M
Free Cash Flow	-2.49B
FCF Per Share	-27.35

Margins

Gross margin is 11.80%, with operating and profit margins of -5.59% and -19.12%.

Gross Margin	11.80%
Operating Margin	-5.59%
Pretax Margin	-16.26%
Profit Margin	-19.12%
EBITDA Margin	-3.98%
EBIT Margin	-5.59%
FCF Margin	n/a

Dividends & Yields

Wellbiotec does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	13.41%
Shareholder Yield	13.41%
Earnings Yield	-698.97%
FCF Yield	-113.94%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

The last stock split was on October 28, 2011. It was a reverse split with a ratio of 0.1.

Last Split Date	Oct 28, 2011
Split Type	Reverse
Split Ratio	0.1

Scores

Wellbiotec has an Altman Z-Score of -7.54 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-7.54
Piotroski F-Score	3